This real-world study aimed to compare the efficacy and safety of PD-1/PD-L1 inhibitor monotherapy versus combination therapy with chemotherapy in elderly patients (≥ 65 years) with advanced NSCLC and develop a prognostic nomogram to guide personalized treatment decisions. Here, PDCD1 is linked to non-small cell lung carcinoma.